Trilaciclib to protect bone marrow after head and neck cancer surgery and chemoradiation
Part of Cancer clinical trials.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer (mouth, throat, voice box) that needed surgery and now requires chemo and radiation.
- Your cancer was stage T1-4N0-3M0 and you had all of it removed with surgery.
- Your surgery report shows at least one high-risk factor, like a positive margin or cancer in lymph nodes.
- You are in good general health (able to do daily activities) and your blood counts and organ function are normal.
- You have not had previous chemotherapy or radiation to the head and neck area, and you don't have HIV, active hepatitis, or other serious illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib to see if it can protect your blood cell counts during treatment for head and neck cancer that has come back or spread. You must not have had chemotherapy before for this stage of cancer.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
This trial tests a drug called trilaciclib, given before chemotherapy to protect your bone marrow (where blood cells are made). It is for people with advanced bile duct or pancreatic cancer who are about to start chemotherapy.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy. It is for people with several types of advanced solid tumors who will receive a specific chemo combination (paclitaxel plus carboplatin) for the first time.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Hear when a new Head and Neck Cancer Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.